Alnylam Pharmaceuticals
ALNY
#566
Rank
ยฃ28.62 B
Marketcap
ยฃ221.90
Share price
1.40%
Change (1 day)
61.98%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

EPS for Alnylam Pharmaceuticals (ALNY)

EPS in 2023 (TTM): -ยฃ3.30

According to Alnylam Pharmaceuticals 's latest financial reports the company's current EPS (TTM) is -ยฃ3.32. In 2022 the company made an earnings per share (EPS) of -ยฃ7.49 a decrease over its 2021 EPS that were of -ยฃ5.81.

EPS history for Alnylam Pharmaceuticals from 2003 to 2023

Annual EPS

Year EPS Change
2023 (TTM)-ยฃ3.30-55.92%
2022-ยฃ7.4929.03%
2021-ยฃ5.81-3.36%
2020-ยฃ6.01-8.48%
2019-ยฃ6.577.67%
2018-ยฃ6.1039.74%
2017-ยฃ4.3612.94%
2016-ยฃ3.8638.84%
2015-ยฃ2.78-32.88%
2014-ยฃ4.15259.44%
2013-ยฃ1.15-31.25%
2012-ยฃ1.6852.94%
2011-ยฃ1.1030.77%
2010-ยฃ0.84-8.77%
2009-ยฃ0.9278.13%
2008-ยฃ0.52-70.78%
2007-ยฃ1.7799.09%
2006-ยฃ0.89-43.88%
2005-ยฃ1.58-82.33%
2004-ยฃ8.95-59.23%
2003-ยฃ21.95

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
-ยฃ1.37-58.64%๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ30.14-1,009.00%๐Ÿ‡บ๐Ÿ‡ธ USA
-ยฃ6.32 90.51%๐Ÿ‡บ๐Ÿ‡ธ USA
-ยฃ0.22-93.43%๐Ÿ‡บ๐Ÿ‡ธ USA
-ยฃ1.36-58.88%๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ3.02-191.00%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
ยฃ2.57-177.38%๐Ÿ‡ซ๐Ÿ‡ท France
-ยฃ1.61-51.34%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel